1,7-Phenanthrolin-4-ol | 23443-29-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 菲咯啉
• 英文名称: 1,7-Phenanthrolin-4-ol
• 英文别名: 4-Hydroxy-1,7-phenanthroline；1H-1,7-phenanthrolin-4-one
• CAS: 23443-29-0
• 化学式: C₁₂H₈N₂O
• 分子量: 196.208
• InChiKey: GCXIAPONMJEKKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-hydroxy-7-phenethylquinoline trans-4-Hydroxy-7-styrylquinoline 在 钯 silica gel 、 二氯甲烷 、 甲醇 作用下， 以 乙醇 为溶剂， 以obtained in the Preparation 2的产率得到1,7-Phenanthrolin-4-ol
  参考文献：
  名称：

  Thioquinolone compounds which have useful pharmaceutical activity

  摘要：

  公开了一种噻喹酮衍生物，对幽门螺杆菌具有高度选择性的抗菌活性。

  公开号：

  US05773449A1

文献信息

• CHIRAL AUXILIARIES
  申请人：Wada Takeshi

  公开号：US20130178612A1

  公开（公告）日：2013-07-11

  Chiral auxiliaries useful for efficiently producing a phosphorus atom-modified nucleic acid derivative with high stereoregularity, and compounds represented by the following the general formula (I) or the general formula (XI) for introducing the chiral auxiliaries.

  对于高立体选择性地生产磷原子修饰的核酸衍生物非常有用的手性辅助剂，以及通过以下一般式(I)或一般式(XI)所代表的化合物引入手性辅助剂。
• Amide derivatives
  申请人：Muto Susumu

  公开号：US20050215645A1

  公开（公告）日：2005-09-29

  A medicament for enhancing an effect of a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a compound represented by the following general formula (I) or a salt thereof: wherein one of R 1 and R 2 represents hydrogen atom and the other represents the formula —X-A wherein A represents hydrogen atom or an acyl group, X represents oxgen atom or NH; one of R 3 and R 4 represents hydrogen atom and the other represents the following formula: wherein Y represents a sulfonyl group or a carbonyl group, R 5 represents a cyclic group, Z represents a single bond or a C 1 to C 4 alkylene group, R 6 represents hydrogen atom or a C 1 to C 6 alkyl group.

  一种用于增强基于DNA损伤作用的癌症治疗效果的药物，其活性成分为以下一般式(I)或其盐表示的化合物：其中R1和R2中的一个代表氢原子，另一个代表式—X-A，其中A代表氢原子或酰基，X代表氧原子或NH；R3和R4中的一个代表氢原子，另一个代表以下式：其中Y代表磺酰基或羰基，R5代表环状基团，Z代表单键或C1到C4烷基烷基，R6代表氢原子或C1到C6烷基基团。
• Optically Active a-Trifluoromethyl-B-Amino Acid Derivative Production Method
  申请人：MICROBIAL CHEMISTRY RESEARCH FOUNDATION

  公开号：US20170283411A1

  公开（公告）日：2017-10-05

  A method for producing an optically active α-trifluoromethyl-β-amino acid derivative, the method including: allowing a compound represented by the following General Formula (1) and a compound represented by the following General Formula (2) to react in the presence of a copper-optically active phosphine complex obtained from a copper compound and an optically active phosphine compound, to thereby obtain an optically active α-trifluoromethyl-β-amino acid derivative represented by the following General Formula (3):

  一种制备光学活性α-三氟甲基-β-氨基酸衍生物的方法，该方法包括：在存在铜化合物和光学活性膦化合物得到的铜-光学活性膦配合物的情况下，使下列通式（1）所代表的化合物和下列通式（2）所代表的化合物反应，从而得到下列通式（3）所代表的光学活性α-三氟甲基-β-氨基酸衍生物。
• INFLAMMATORY CYTOKINE RELEASE INHIBITOR
  申请人：MUTO Susumu

  公开号：US20090192122A2

  公开（公告）日：2009-07-30

  A medicament having inhibitory activity against NF-κB activation, which comprises a compound represented by the following general formula (I) or a pharmacologically acceptable salt as an active ingredient: wherein X represents a connecting group, A represents hydrogen atom or acetyl group, E represents an aryl group or a heteroaryl group, and ring X represents an arene or a heteroarene.

  一种具有抑制NF-κB激活活性的药物，其包括以下通式(I)所表示的化合物或其药理学上可接受的盐作为活性成分：其中X代表连接基，A代表氢原子或乙酰基，E代表芳基或杂芳基，环X代表芳烃或杂芳烃。
• Nf-kb activation inhibitors
  申请人：Muto Susumu

  公开号：US20060089395A1

  公开（公告）日：2006-04-27

  A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is circle around (1)} a fused polycyclic heteroaryl group wherein the ring which binds directly to —CONH— group in the formula (I) is a benzene ring, circle around (2)} unsubstituted thiazol-2-yl group, or circle around (3)} unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above.

  一种药物具有抑制NF-κB活化作用，其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分，其中A代表氢原子或乙酰基，E代表2,5-二取代或3,5-二取代苯基或单环或融合的多环杂环芳基，其可以被取代，但在所述杂环芳基是圆圈(1)}在公式(I)中直接结合—CONH—基团的环为苯环的融合多环杂环芳基，圆圈(2)}未取代的噻唑-2-基团，或者圆圈(3)}未取代的苯并噻唑-2-基团时，不包括该化合物，环Z代表一个芳香烃，除了由公式—O-A所表示的基团外，它也可以有一个或多个取代基，其中A具有与上述定义相同的含义，公式—CONH-E所表示的基团E具有与上述定义相同的含义。